ARL6IP4

Across TCGA pan-cancer cohorts, ARL6IP4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ARL6IP4 data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ARL6IP4 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ARL6IP4 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where ARL6IP4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	1.000	0.716	<.001	15	view →
PDAC	OS	Median	All	0.917	0.732	.007	9	view →
CCRCC	DFS	Tertile	All	0.656	1.000	.025	6	view →
GBM	OS	Median	All	0.808	0.896	.012	4	view →
LSCC	OS	Median	All	1.000	0.925	.014	3	view →
HNSC	OS	Median	All	1.000	0.959	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ARL6IP4–LUAD (OS)

Open the LUAD breakdown →